文献速递糖尿病

2型糖尿病中HbA1c与全因死亡率的关联随血糖变异度不同而变化

Association of HbA1c With All-cause Mortality Across Varying Degrees of Glycemic Variability in Type 2 Diabetes.
PubMed 文献 · J Clin Endocrinol Metab · 2021-01-01

这项前瞻性单中心研究纳入6090例住院2型糖尿病患者,用连续3天血糖监测计算血糖变异系数(CV),随访中位6.8年。结果显示,在血糖CV最低和中间三分位组,HbA1c≥8.0%与全因死亡风险显著升高相关;但在血糖CV最高三分位组,HbA1c与死亡率无显著关联。

要点

  • 血糖变异度低或中等时,HbA1c≥8.0%与全因死亡风险升高相关。
  • 血糖变异度最高时,HbA1c与全因死亡无显著关联。
  • 高血糖变异度患者可能需要HbA1c以外的血糖控制指标。

核心结论

  • 在高血糖变异度的2型糖尿病患者中,HbA1c可能不是全因死亡率的稳健标志物。

研究设计与样本

  • 前瞻性单中心研究,纳入6090例住院2型糖尿病患者,用连续3天血糖监测计算血糖CV。

主要发现

  • 中位随访6.8年期间,815例患者死亡。
  • 血糖CV最低三分位组中,HbA1c≥8.0%者全因死亡风险比HbA1c 6.0%-6.9%者高136%(95%CI 1.46-3.81)。
  • 血糖CV中间三分位组中,HbA1c≥8.0%者全因死亡风险比HbA1c 6.0%-6.9%者高92%(95%CI 1.22-3.03)。
  • 血糖CV最高三分位组中,HbA1c与全因死亡无显著关联。

临床怎么用

  • 对血糖变异度高的2型糖尿病患者,评估死亡风险时不应仅依赖HbA1c。
  • 高血糖变异度患者可能需要探索新的血糖控制指标以优化管理。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: The interaction of glycated hemoglobin A1c (HbA1c) and glycemic variability in relation to diabetes-related outcomes remains unknown. OBJECTIVE: To evaluate the relationship between HbA1c and all-cause mortality across varying degrees of glycemic variability in patients with type 2 diabetes. DESIGN, SETTING, AND PATIENTS: This was a prospective study conducted in a single referral center. Data of 6090 hospitalized patients with type 2 diabetes was analyzed. Glucose coefficient of variation [coefficient of variation (CV)] was obtained as the measure of glycemic variability by using continuous glucose monitoring for 3 days. Cox proportional hazards regression models were used to estimate hazard ratios and 95% CIs for all-cause mortality. RESULTS: During a median follow-up of 6.8 years, 815 patients died. In patients with the lowest and middle tertiles of glucose CV, HbA1c ≥ 8.0% was associated with 136% (95% CI 1.46-3.81) and 92% (95% CI 1.22-3.03) higher risks of all-cause mortality, respectively, as compared with HbA1c 6.0%-6.9%, after adjusting for confounders. However, a null association of HbA1c with mortality was found in patients with the highest tertile of glucose CV. CONCLUSIONS: HbA1c may not be a robust marker of all-cause mortality in patients with high degree of glycemic variability. New metrics of glycemic control may be needed in these individuals to achieve better diabetes management.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Lu J, Wang C, Cai J, et al. Association of HbA1c With All-cause Mortality Across Varying Degrees of Glycemic Variability in Type 2 Diabetes. J Clin Endocrinol Metab. 2021. PMID: 34279663. doi:10.1210/clinem/dgab532

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。